0 NASDAQ Companies - March 7, 2024Vital Farms Reports Fourth Quarter and Fiscal Year 2023 Financial ResultsRecord Fourth Quarter Net Revenue of $135.8 million, up 23.4% versus Prior Year PeriodProvides Fiscal Year 2024 Outlook AUSTIN, Texas, […]Read More
0 TSX News - March 7, 2024Bitfarms Reports Fourth Quarter and Full Year 2023 Results– Earned 1,236 BTC in Q4 2023 and 4,928 BTC in 2023 –– Improved Q4 2023 gross mining margin to […]Read More
0 NASDAQ Companies - March 7, 2024Altisource Announces Fourth Quarter and Full Year 2023 Financial ResultsLUXEMBOURG, March 07, 2024 (GLOBE NEWSWIRE) — Altisource Portfolio Solutions S.A. (“Altisource” or the “Company”) (NASDAQ: ASPS), a leading provider […]Read More
0 TSX News - March 7, 2024KP Tissue Releases Fourth Quarter and Full Year 2023 Financial ResultsMISSISSAUGA, Ontario, March 07, 2024 (GLOBE NEWSWIRE) — KP Tissue Inc. (KPT) (TSX: KPT) reports the Q4 2023 and full […]Read More
0 NASDAQ Companies - March 7, 2024Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational HighlightsPDUFA target action date is March 16, 2024, for the Company’s sNDA. If approved, the Company is prepared for launch […]Read More
0 NASDAQ Companies - March 7, 2024Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHDCHARLESTOWN, Mass., March 07, 2024 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic […]Read More
0 NASDAQ Companies - March 7, 2024Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update– Additional monotherapy dose-escalation data from ongoing Phase 1/1b clinical trial of WTX-124 expected to be presented in the first […]Read More
0 NASDAQ Companies - March 7, 2024Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business UpdateTopline data from Phase 2b study of Descartes-08, the Company’s potential first-in-class mRNA CAR-T cell therapy, in myasthenia gravis (MG) […]Read More
0 NASDAQ Companies - March 7, 2024Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateOn-track to report topline Phase 3 data from the KOASTAL-1 study with navacaprant in MDD in the second half of […]Read More
0 NASDAQ Companies - March 7, 2024Harvard Bioscience Announces Fourth Quarter 2023 Financial ResultsQ4 Revenues of $28.2 million Q4 Gross Margin of 58.0% (230 bps year-over-year improvement) Q4 operating income of $0.3 million, […]Read More